Oligonucleotide-containing pharmacological compositions and their use

1. A composition suitable for administration in a mammal suffering from a pathological disorder or disease comprising at least two modified oligonucleotides,

wherein a first and a second modified oligonucleotide each comprises about seven to seventy-five nucleotides containing seven or more contiguous ribose groups linked by achiral 5′ to 3′ internucleotide phosphate linkages,

wherein at least one ribose group of at least one of said modified oligonucleotides has a modified 2′ substituent, wherein the 5′ and 3′ ends of at least one of said modified oligonucleotides are blocked,

wherein said first modified oligonucleotide is SEQ ID NO: 1, wherein said second modified oligonucleotide is SEQ ID NO: 16, and

wherein said first modified oligonucleotide is complementary to a region of a first gene associated with said pathological disorder or disease and said second modified oligonucleotide is complementary to a region of a second gene associated with said pathological disorder or disease,

wherein said pathological disorder is selected from the group consisting of abnormal appetite, hypertension, hypercholesterolemia, hyperlipidemia, erectile dysfunction, eczema, depression, anxiety, stress, inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, renal stones, gall stones, constipation, migraine headache, seizure, multiple sclerosis, polymyositis, fibromyalgia, Parkinson's disease, ALS, chronic pain, pre-menstrual syndrome, chronic allergies, sinusitis, colds, trauma, carpal tunnel syndrome, chronic fatigue syndrome, rosacea, arthritis, psoriasis, prostatitis, inflammation, heartburn, infection, and poison ivy.

2. The composition of claim 1 wherein said composition further contains a pharmaceutically acceptable excipient.

3. The composition of claim 1 wherein said composition further contains a cosmetically acceptable excipient.

4. A nutritional supplement comprising

two or more modified oligonucleotides each comprising about seven to seventy-file nucleotides containing seven or more contiguous ribose groups linked by achiral 5′ to 3′ internucleoside phosphate linkages,

wherein at least one ribose group of at least one of said modified oligonucleotides has a modified 2′ substituent,

wherein the 5′ and 3′ ends of at least one of said modified oligonucleotides are blocked, wherein said first modified oligonucleotide is SEQ ID NO: 1,

wherein said second modified oligonucleotide is SEQ ID NO: 16,

wherein each of said two or more modified oligonucleotides is complementary to a region of a gene associated with said pathological disorder or disease, and

wherein said pathological disorders are selected from the group consisting of: stress, migraine headache, minor or temporary pain, prostatitis, premenstrual syndrome, menstrual cramping, bloating, nausea, irritability, nervous tension, anxiety, and lack of control of appetite.

5. The nutritional supplement of claim 4 further comprising one or more nutritional supplements selected from the group consisting of selenium, vitamin E, vitamin C and coenzyme Q10.

6. The composition of claim 1 or nutritional supplement of claim 4 wherein one or more of said modified oligonucleotides is present at a concentration effective to reduce the expression of its gene.

7. The composition of claim 1 or nutritional supplement of claim 4 wherein said modified oligonucleotides are suitable for oral administration.

8. The composition of claim 1 , or nutritional supplement of claim 4 , wherein said first and second modified oligonucleotides are complementary to a region of said gene selected from the group consisting of the 5′ UTR region, translational start site and transitional termination site.

9. The composition of claim 1 or nutritional supplement of claim 4 , wherein said 2′ substituent is selected from the group consisting of methoxy, propoxy, methoxy-ethoxy, fluorine, chlorine, bromine and iodine.

10. The composition of claim 1 or nutritional supplement of claim 4 wherein said composition further contains an excipient suitable for oral consumption.

11. The composition of claim 1 or the nutritional supplement of claim 4 , wherein said mammal is a human.

12. The composition of claim 1 or the nutritional supplement of claim 4 , wherein said 5′ and 3′ ends comprise a butanol.